Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Thatcher

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Current Opinion in Oncology|February 24, 2005
Chemotherapy for advanced non-small cell lung cancer patients with performance status 2Fiona H Blackhall, Jaishree Bhosle, Nicholas Thatcher
Expert Opinion on Pharmacotherapy|June 15, 2005
Erlotinib in non-small cell lung cancer: a reviewFiona H Blackhall, Shazza Rehman, Nicholas Thatcher
Expert Opinion on Pharmacotherapy|November 27, 2007
Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancerSylke Nagel, Raffaele Califano, Nicholas Thatcher, et al.
Future Oncology (London, England)|February 23, 2019
Biosimilars: what the oncologist should knowMarc Thill, Nicholas Thatcher, Vladimir Hanes, et al.
Expert Opinion on Pharmacotherapy|June 17, 2005
Perspectives on novel therapies for bronchial carcinomaFiona Blackhall, Pavlos I Papakotoulas, Sarah Danson, et al.
Lung Cancer (Amsterdam, Netherlands)|September 23, 2011
Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesotheliomaBeth Woods, Noman Paracha, David A Scott, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 1, 2009
No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant dataNeil Hawkins, David A Scott, Beth S Woods, et al.
Current Medical Research and Opinion|July 15, 2015
'Dos and don'ts' in the management of hyponatremiaSimon Aylwin, Volker Burst, Alessandro Peri, et al.
Lung Cancer (Amsterdam, Netherlands)|May 24, 2005
A randomised controlled trial of pre-operative chemotherapy followed, if feasible, by resection versus radiotherapy in patients with inoperable stage T3, N1, M0 or T1-3, N2, M0 non-small cell lung cancerRichard J Stephens, David J Girling, Penelope Hopwood, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancerRichard Booton, Richard Booten, Tim Ward, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Current Opinion in Oncology|February 24, 2005
Chemotherapy for advanced non-small cell lung cancer patients with performance status 2Fiona H Blackhall, Jaishree Bhosle, Nicholas Thatcher
Expert Opinion on Pharmacotherapy|June 15, 2005
Erlotinib in non-small cell lung cancer: a reviewFiona H Blackhall, Shazza Rehman, Nicholas Thatcher
Expert Opinion on Pharmacotherapy|November 27, 2007
Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancerSylke Nagel, Raffaele Califano, Nicholas Thatcher, et al.
Future Oncology (London, England)|February 23, 2019
Biosimilars: what the oncologist should knowMarc Thill, Nicholas Thatcher, Vladimir Hanes, et al.
Expert Opinion on Pharmacotherapy|June 17, 2005
Perspectives on novel therapies for bronchial carcinomaFiona Blackhall, Pavlos I Papakotoulas, Sarah Danson, et al.
Lung Cancer (Amsterdam, Netherlands)|September 23, 2011
Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesotheliomaBeth Woods, Noman Paracha, David A Scott, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 1, 2009
No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant dataNeil Hawkins, David A Scott, Beth S Woods, et al.
Current Medical Research and Opinion|July 15, 2015
'Dos and don'ts' in the management of hyponatremiaSimon Aylwin, Volker Burst, Alessandro Peri, et al.
Lung Cancer (Amsterdam, Netherlands)|May 24, 2005
A randomised controlled trial of pre-operative chemotherapy followed, if feasible, by resection versus radiotherapy in patients with inoperable stage T3, N1, M0 or T1-3, N2, M0 non-small cell lung cancerRichard J Stephens, David J Girling, Penelope Hopwood, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancerRichard Booton, Richard Booten, Tim Ward, et al.
Pageof 4